ALK-Abelló A/S
ALK-B
Rang in Aktien
#2413
ALK-Abelló A/S is a global leader in allergy solutions, with operations... ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
Aktienkurs
$36.42
Marktkapitalisierung
$8.08B
Veränderung (1 Tag)
-3.54%
Veränderung (1 Jahr)
12.58%
Land
DK
Handel ALK-Abelló A/S (ALK-B)
Kategorie
Healthcare
Kursverlauf für ALK-Abelló A/S (ALK-B)
Höchster Schlusskurs: $33.18 am 2026-10-01
Niedrigster Schlusskurs: $4.68 am 2009-11-01
Niedrigster Schlusskurs: $4.68 am 2009-11-01
Kursverlauf der Aktie von ALK-Abelló A/S von 2009 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | -1.03% |
| 2025 | 62.35% |
| 2024 | 75.96% |
| 2023 | -10.08% |
| 2022 | -41.52% |
| 2021 | 84.43% |
| 2020 | 3.84% |
| 2019 | 35.14% |
| 2018 | 16.65% |
| 2017 | 25.63% |
| 2016 | 3.30% |
| 2015 | 10.00% |
| 2014 | 7.87% |
| 2013 | 53.73% |
| 2012 | 15.92% |
| 2011 | -22.10% |
| 2010 | -20.73% |
| 2009 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
